<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>                  The efficacy of FASLODEX 500 mg versus FASLODEX 250 mg was compared in Study 1. The efficacy of FASLODEX 250 mg was compared to anastrozole in Studies 2 and 3.  <BR>                  <BR>                     <BR>                        Comparison of FASLODEX 500 mg and FASLODEX 250 mg (Study 1)<BR>                     <BR>                  <BR>                  A Phase 3 randomized, double-blind, controlled clinical trial (Study 1) was completed in 736 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease. This trial compared the efficacy and safety of FASLODEX 500 mg (n=362) with FASLODEX 250 mg (n=374).<BR>                  FASLODEX 500 mg was administered as two 5 mL injections each containing FASLODEX 250 mg/5mL, one in each buttock, on Days 1, 15, 29 and every 28 (+/- 3) days thereafter. FASLODEX 250 mg was administered as two 5 mL injections (one containing FASLODEX 250 mg/5mL injection plus one placebo injection), one in each buttock, on Days 1, 15 (2 placebo injections only), 29 and every 28 (+/- 3) days thereafter.<BR>                  The median age of study participants was 61. All patients had ER+ advanced breast cancer. Approximately 30% of subjects had no measurable disease. Approximately 55% of patients had visceral disease.<BR>                  Results of Study 1 are summarized in Table 4. The efficacy of FASLODEX 500 mg was compared to that of FASLODEX 250 mg. Figure 4 shows a Kaplan-Meier plot of the Progression Free Survival (PFS) data after a minimum follow-up duration of 18 months demonstrating statistically significant superiority of FASLODEX 500 mg vs FASLODEX 250 mg.  In the initial Overall Survival (OS) analysis after a minimum follow-up duration of 18 months, there was no statistically significant difference in OS between the two treatment groups. After a minimum follow-up duration of 50 months, an updated OS analysis was performed. Figure 5 shows a Kaplan-Meier plot of the updated OS data.<BR>                  Table 4: Efficacy Results Study 1: Intent To Treat (ITT) Population<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                     <col width="38%"/><BR>                     <col width="38%"/><BR>                     <col width="38%"/><BR>                     <tbody><BR>                        <tr><BR>                           <td styleCode="Rrule Botrule Lrule Toprule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">Endpoint</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">Fulvestrant 500 mg</content><BR>                              </paragraph><BR>                              <paragraph><BR>                                 <content styleCode="bold">(N=362)</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">Fulvestrant 250 mg</content><BR>                              </paragraph><BR>                              <paragraph><BR>                                 <content styleCode="bold">(N=374)</content><BR>                              </paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">PFS</content><BR>                                 <footnote ID="_Ref328390774">PFS (Progression Free Survival) =  the time between randomization and the earliest of progression or death from any cause. Minimum follow-up duration of 18 months.</footnote><BR>                              </paragraph><BR>                              <paragraph>Median (months)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>6.5</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>5.4</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph>Hazard Ratio<footnote ID="_Ref328391681">Hazard ratio &lt; 1 favors FASLODEX 500 mg.</footnote> (95% CI<footnote ID="_Ref328391700">CI=Confidence Interval</footnote> )</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>0.80 (0.68-0.94)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph>p-value</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>0.006</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td align="center" colspan="3" styleCode="Rrule Lrule Botrule "/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">OS</content><BR>                                 <footnote ID="_Ref328391986">OS=Overall Survival</footnote><BR>                                 <content styleCode="bold"> Updated Analysis</content><BR>                                 <footnoteRef IDREF="_Ref328391986"/><BR>                              </paragraph><BR>                              <paragraph>(% patients who died)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>261 (72.1%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>293 (78.3%)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph>Median OS (months)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>26.4</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>22.3</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph>Hazard Ratio<footnoteRef IDREF="_Ref328391681"/> (95% CI<footnoteRef IDREF="_Ref328391700"/>)</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>0.81 (0.69-0.96)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td align="center" colspan="3" styleCode="Rrule Lrule Botrule "/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">ORR</content><BR>                                 <footnote ID="_Ref328393826">ORR  (Objective Response Rate), as defined as number (%) of patients with complete response or partial response, was analyzed in the evaluable patients with measureable disease at baseline (fulvestrant 500 mg N=240; fulvestrant 250 mg N=261). Minimum follow-up duration of 18 months.</footnote><BR>                                 <content styleCode="bold"/>(95% CI<footnoteRef IDREF="_Ref328391700"/>)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>13.8% (9.7%, 18.8%)</paragraph><BR>                              <paragraph>(33/240)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Lrule Toprule Botrule "><BR>                              <paragraph>14.6% (10.5%, 19.4%)</paragraph><BR>                              <paragraph>38/261)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Botrule Lrule Toprule "/><BR>                           <td align="center" styleCode="Rrule Botrule Lrule Toprule "/><BR>                           <td align="center" styleCode="Rrule Botrule Lrule Toprule "/><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR><BR>                     Figure 4 Kaplan-Meier PFS: Study 1 ITT Population<BR>                  <BR>                  <BR>                  <BR>                     Figure 5 Kaplan-Meier OS (minimum follow-up duration of 50 months): Study 1 ITT Population<BR>                  <BR>                  <BR>                  <BR>                     <BR>                        Comparison of FASLODEX 250 mg and Anastrozole 1 mg in Combined Data (Studies 2 and 3)<BR>                     <BR>                  <BR>                  Efficacy of FASLODEX was established by comparison to the selective aromatase inhibitor anastrozole in two randomized, controlled clinical trials (one conducted in North America, Study 2; the other predominantly in Europe, Study 3) in postmenopausal women with locally advanced or metastatic breast cancer. All patients had progressed after previous therapy with an antiestrogen or progestin for breast cancer in the adjuvant or advanced disease setting. <BR>                  The median age of study participants was 64. 81.6% of patients had ER+ and/or PgR+ tumors. Patients with ER- /PgR- or unknown tumors were required to have demonstrated a prior response to endocrine therapy. Sites of metastases occurred as follows: visceral only 18.2%; viscera – liver involvement 23.0%; lung involvement 28.1%; bone only 19.7%; soft tissue only 5.2%; skin and soft tissue 18.7%.<BR>                  In both trials, eligible patients with measurable and/or evaluable disease were randomized to receive either FASLODEX 250 mg intramuscularly once a month (28 days + 3 days) or anastrozole 1 mg orally once a day. All patients were assessed monthly for the first three months and every three months thereafter. Study 2 was a double-blind, randomized trial in 400 postmenopausal women. Study 3 was an open-label, randomized trial conducted in 451 postmenopausal women. Patients on the FASLODEX arm of Study 2 received two separate injections (2 X 2.5 mL), whereas FASLODEX patients received a single injection (1 X 5 mL) in Study 3. In both trials, patients were initially randomized to a 125 mg per month dose as well, but interim analysis showed a very low response rate, and low dose groups were dropped. <BR>                  Results of the trials, after a minimum follow-up duration of 14.6 months, are summarized in Table 5. The effectiveness of FASLODEX 250 mg was determined by comparing Objective Response Rate (ORR) and Time to Progression (TTP) results to anastrozole 1 mg, the active control. The two studies ruled out (by one-sided 97.7% confidence limit) inferiority of FASLODEX to anastrozole of 6.3% and 1.4% in terms of ORR. There was no statistically significant difference in overall survival (OS) between the two treatment groups after a follow-up duration of 28.2 months in Study 2 and 24.4 months in Study 3.<BR>                  <BR>                     Table 5: Efficacy Results<BR>                  <BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                     <col width="40%"/><BR>                     <col width="15%"/><BR>                     <col width="14%"/><BR>                     <col width="15%"/><BR>                     <col width="14%"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Botrule "/><BR>                           <th colspan="2" styleCode="Botrule "><BR>                              <content styleCode="bold">Study 2 </content><BR>                              <br/><BR>                              <content styleCode="bold">(Double-Blind)</content><BR>                           </th><BR>                           <th colspan="2" styleCode="Botrule "><BR>                              <content styleCode="bold">Study 3 </content><BR>                              <br/><BR>                              <content styleCode="bold">(Open-Label)</content><BR>                           </th><BR>                        </tr><BR>                        <tr><BR>                           <th styleCode="Botrule "/><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">FASLODEX</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">Anastrozole</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">FASLODEX</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">Anastrozole</content><BR>                           </th><BR>                        </tr><BR>                        <tr><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">Endpoint</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">250 mg </content><BR>                              <br/><BR>                              <content styleCode="bold">(n=206)</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">1 mg </content><BR>                              <br/><BR>                              <content styleCode="bold">(n=194)</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">250 mg </content><BR>                              <br/><BR>                              <content styleCode="bold">(n=222)</content><BR>                           </th><BR>                           <th styleCode="Botrule "><BR>                              <content styleCode="bold">1 mg      </content><BR>                              <br/><BR>                              <content styleCode="bold">(n=229)</content><BR>                           </th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Objective tumor response</paragraph><BR>                           </td><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Number (%) of subjects </paragraph><BR>                              <paragraph>with CR<footnote ID="_RefFN1257123955-1">CR = Complete Response</footnote> + PR<footnote ID="_RefFN1257124012-1">PR = Partial Response</footnote><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>35 (17.0)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>33 (17.0)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>45 (20.3)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>34 (14.9)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>% Difference in Tumor </paragraph><BR>                              <paragraph>Response Rate </paragraph><BR>                              <paragraph>(FAS<footnote ID="_RefFN1257124110-1">FAS = FASLODEX</footnote>  &#8212;ANA<footnote ID="_RefFN1257124174-1">ANA = anastrozole</footnote>) </paragraph><BR>                              <paragraph>2&#8211;sided 95.4% CI<footnote ID="_RefFN1257124244-1">CI = Confidence Interval</footnote><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Botrule "><BR>                              <paragraph>0.0 </paragraph><BR>                              <paragraph>(-6.3, 8.9)</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Botrule "><BR>                              <paragraph>5.4 </paragraph><BR>                              <paragraph>(-1.4, 14.8)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Time to progression (TTP)</paragraph><BR>                              <paragraph>Median TTP (days)</paragraph><BR>                           </td><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>165</paragraph><BR>                           </td><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>103</paragraph><BR>                           </td><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>166</paragraph><BR>                           </td><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>156</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Hazard ratio <footnote ID="_RefFN1284601971-1">Hazard ratio &lt;1 favors FASLODEX</footnote><BR>                              </paragraph><BR>                              <paragraph>2-sided 95.4% CI<sup>&#182;</sup><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Botrule "><BR>                              <paragraph>0.9 </paragraph><BR>                              <paragraph>(0.7, 1.1)</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Botrule "><BR>                              <paragraph>1.0 </paragraph><BR>                              <paragraph>(0.8, 1.2)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Stable Disease for &#8805; 24 	weeks (%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>26.7</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>19.1</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>24.3</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>30.1</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Overall Survival (OS)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "/><BR>                           <td align="center" styleCode="Botrule "/><BR>                           <td align="center" styleCode="Botrule "/><BR>                           <td align="center" styleCode="Botrule "/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Died n (%) </paragraph><BR>                              <paragraph>Median Survival (days)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>152 (73.8%) </paragraph><BR>                              <paragraph>844</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>149 (76.8%) </paragraph><BR>                              <paragraph>913</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>167 (75.2%) </paragraph><BR>                              <paragraph>803</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Botrule "><BR>                              <paragraph>173 (75.5%) </paragraph><BR>                              <paragraph>736</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "><BR>                              <paragraph>Hazard Ratio<footnoteRef IDREF="_RefFN1284601971-1"/><BR>                              </paragraph><BR>                              <paragraph>(2-sided 95% CI<sup>&#182;</sup>)</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Botrule "><BR>                              <paragraph>0.98 </paragraph><BR>                              <paragraph>(0.78, 1.24)</paragraph><BR>                           </td><BR>                           <td align="center" colspan="2" styleCode="Botrule "><BR>                              <paragraph>0.97 </paragraph><BR>                              <paragraph>(0.78, 1.21)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                           <td styleCode="Botrule "/><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>There are no efficacy data for the use of FASLODEX in premenopausal women with advanced breast cancer (women with functioning ovaries as evidenced by menstruation and/or premenopausal LH, FSH and estradiol levels).<BR>               <BR>               <BR>               <BR>                  <BR>                     fig 4 kaplan-maier PFS: Study 1 ITT Population<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     figure 5 kaplan meier OS study 1 ITT population<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>